FDA limits leucovorin to a rare folate disorder, not autism broadly
Why it matters
The September announcement framed leucovorin as an autism treatment. The March follow-through narrowed it sharply, a reminder that a label authorization and a broad autism indication are not the same thing.
As of March 2026, the FDA has not approved leucovorin (folinic acid) as a treatment for autism broadly. The agency limited the drug’s indication to patients with FOLR1-related cerebral folate transport deficiency, an ultra-rare genetic condition affecting fewer than 50 people worldwide.
The FDA said current evidence is insufficient to establish efficacy for autism more generally. The American Academy of Pediatrics does not recommend routine use for autism, and many health systems continue to withhold prescriptions pending further research.
The outcome is narrower than the broad treatment avenue described when the administration first announced the leucovorin label update in September 2025. NIH confirmatory trials remain ongoing. For now, that narrow authorization is where the question stands.
Source
FDARelated coverage
NIH finalizes its $51 million autism research initiative: 13 projects, none on vaccines
The administration promised a hard look at what causes autism. The money is now committed, and it is worth being precise about where it went: the largest federal award pool of the year funds thirteen projects, and not one of them studies vaccines. The vaccine question sits with a separate, much smaller contract that has yet to report anything.
Post“Kennedy is the saving grace”: Trump moves to remake the childhood schedule, and what is actually in force
In the span of six weeks the President signed an order cutting routine childhood vaccines from 18 diseases to 11, then stood beside Robert F. Kennedy Jr. and proposed splitting shots into five smaller doses. A viral clip called it a schedule of 72 shots reduced to 11 “by the stroke of a pen.” That is the biggest shift in federal vaccine posture in a generation, and it is also not yet law. Here is the record, and the reaction, side by side.
The record behind the witness: Hulscher's 39 studies and why legislators keep calling him
Nicolas Hulscher has become the reform movement's most-requested expert witness, appearing before both the U.S. Senate and the Michigan House inside a single year. Behind those appearances is a specific, checkable body of published work, and readers deserve to see what it actually consists of rather than take the label 'epidemiologist' on faith.